BACKGROUND & OBJECTIVES: Significant progress has been made towards eradication of poliomyelitis in India. Surveillance for acute flaccid paralysis (AFP) has reached high standards. Among the 3 types of polioviruses, type 2 had been eliminated in India and eradicated globally as of October 1999. However, we isolated wild poliovirus type 2 from a small number of polio cases in northern India in 2000 and again during December 2002 to February 2003. Using molecular tools the origin, of the wild type 2 poliovirus was investigated. METHODS: Polioviruses isolated from stool samples collected from patients with AFP were differentiated as wild virus or Sabin vaccine-like by ELISA and probe hybridization assays. Complete VP1 gene nucleotide sequences of the wild type 2 poliovirus isolates were determined by reverse transcriptase polymerase chain reaction (RT-PCR), followed by cycle sequencing. VP1 nucleotide sequences were compared with those of wild type 2 polioviruses that were indigenous in India in the past as well as prototype/laboratory strains and the GenBank database. RESULTS: Wild poliovirus type 2 was detected in stool samples from 6 patients with AFP in western Uttar Pradesh and 1 in Gujarat. In addition, the virus was isolated from one healthy contact child and from environmental sewage sample in Moradabad where three of these patients were reported. These isolates were identified as genetically closely related to laboratory reference strain MEF-1. Molecular characterization of the isolates confirmed that there was no evidence of extensive person-to-person transmission of the virus in the community. INTERPRETATION & CONCLUSION: Laboratory reference strain (MEF-1) of poliovirus type 2 caused paralytic poliomyelitis in 10 patients in September 2000 and November 2002 to February 2003. The origin of the virus was some laboratory as yet not identified. This episode highlights the urgent need for stringent containment of wild poliovirus containing materials in the laboratories across the country in order to prevent recurrence of such incidents.
BACKGROUND & OBJECTIVES: Significant progress has been made towards eradication of poliomyelitis in India. Surveillance for acute flaccid paralysis (AFP) has reached high standards. Among the 3 types of polioviruses, type 2 had been eliminated in India and eradicated globally as of October 1999. However, we isolated wild poliovirus type 2 from a small number of polio cases in northern India in 2000 and again during December 2002 to February 2003. Using molecular tools the origin, of the wild type 2 poliovirus was investigated. METHODS: Polioviruses isolated from stool samples collected from patients with AFP were differentiated as wild virus or Sabin vaccine-like by ELISA and probe hybridization assays. Complete VP1 gene nucleotide sequences of the wild type 2 poliovirus isolates were determined by reverse transcriptase polymerase chain reaction (RT-PCR), followed by cycle sequencing. VP1 nucleotide sequences were compared with those of wild type 2 polioviruses that were indigenous in India in the past as well as prototype/laboratory strains and the GenBank database. RESULTS: Wild poliovirus type 2 was detected in stool samples from 6 patients with AFP in western Uttar Pradesh and 1 in Gujarat. In addition, the virus was isolated from one healthy contact child and from environmental sewage sample in Moradabad where three of these patients were reported. These isolates were identified as genetically closely related to laboratory reference strain MEF-1. Molecular characterization of the isolates confirmed that there was no evidence of extensive person-to-person transmission of the virus in the community. INTERPRETATION & CONCLUSION: Laboratory reference strain (MEF-1) of poliovirus type 2 caused paralytic poliomyelitis in 10 patients in September 2000 and November 2002 to February 2003. The origin of the virus was some laboratory as yet not identified. This episode highlights the urgent need for stringent containment of wild poliovirus containing materials in the laboratories across the country in order to prevent recurrence of such incidents.
Authors: Glynis Dunn; Dimitra Klapsa; Thomas Wilton; Lindsay Stone; Philip D Minor; Javier Martin Journal: PLoS Pathog Date: 2015-08-27 Impact factor: 6.823
Authors: Michael Famulare; Christian Selinger; Kevin A McCarthy; Philip A Eckhoff; Guillaume Chabot-Couture Journal: PLoS Biol Date: 2018-04-27 Impact factor: 8.029
Authors: Mami Taniuchi; Michael Famulare; Khalequ Zaman; Md Jashim Uddin; Alexander M Upfill-Brown; Tahmina Ahmed; Parimalendu Saha; Rashidul Haque; Ananda S Bandyopadhyay; John F Modlin; James A Platts-Mills; Eric R Houpt; Mohammed Yunus; William A Petri Journal: Lancet Infect Dis Date: 2017-07-07 Impact factor: 25.071
Authors: Barbara P Sanders; Isabel de Los Rios Oakes; Vladimir van Hoek; Viki Bockstal; Tobias Kamphuis; Taco G Uil; Yutong Song; Gillian Cooper; Laura E Crawt; Javier Martín; Roland Zahn; John Lewis; Eckard Wimmer; Jerome H H V Custers; Hanneke Schuitemaker; Jeronimo Cello; Diana Edo-Matas Journal: PLoS Pathog Date: 2016-03-31 Impact factor: 6.823
Authors: Elizabeth B Brickley; Wendy Wieland-Alter; Ruth I Connor; Margaret E Ackerman; Austin W Boesch; Minetaro Arita; William C Weldon; Miguel G O'Ryan; Ananda S Bandyopadhyay; Peter F Wright Journal: Clin Infect Dis Date: 2018-10-30 Impact factor: 9.079